Evaluation of molecular biomarkers for hepatocellular carcinoma (HCC) therapy to predict progression free survival after therapy

A/Prof Adam Testro0 个研究点目标入组 150 人开始时间: 2023年7月12日最近更新: 2023年7月18日

适应症

试验速览

暂无简介。

•Study question 1:
•1.Age 18 or greater
•2.Adult patients undergoing therapy for Hepatocellular Carcinoma (HCC)
•a.Therapy may include 3 broad categories
•i.Interventional radiology
•1.Transarterial Chemo-embolisaion (TACE)
•2.Microwave ablation (MWA)
•3.Radiofrequency ablation (RFA)
•4.Selective Internal Radiation-Therapy (SIRT)
•5.Percutaneous Ethanol Injection (PEI)
•1.Liver resection
•2.Liver transplantation
•iii.Radiation oncology
•1.Stereotactic Body Radiation Therapy (SBRT)
•iv.Medical oncology
•1.Systemic therapy
•3.Informed consent
•Study Question 2:
•1.Age 18 or greater
•2.Adult patients diagnosed with HCC
•a.Referred to the HCC Multi-disciplinary meeting for consideration of liver transplant assessment or
•b.Referred to the pre-liver transplant clinic for consideration of liver transplant assessment
•3.Patients must have been informed by a clinician from the Liver Transplant Unit that they are being considered for liver transplant assessment, with documentation in medical records
•a.Patients may or may not yet have been formally assessed or wait listed for liver transplantation
•4.Patients may or may not have undergone prior therapy for HCC
•5.Informed consent

发起方

A/Prof Adam Testro